FDA approves HIV prevention drug taken as twice-yearly injection
The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.
The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.
Daniel O'Day, Gilead's chairman and chief executive officer, called the approval a "milestone moment in the decades-long fight against HIV."
"Yeztugo will help us prevent HIV on a scale never seen before. We now have a way to end the HIV epidemic once and for all," O'Day said in a news release.
According to the Centers for Disease Control and Prevention, there were 31,800 estimated new HIV infections in the United States in 2022, the most recent year with available data.
While the drug's approval meets an existing need, the Trump administration's funding decisions have rolled back progress for a vaccine.
Last month, the administration moved to end funding for a broad swath of HIV vaccine research, saying current approaches are enough to counter the virus.
Dr. Barton Ford Haynes, the director of the Duke Human Vaccine Institute, recently told CBS News lenacapavir is a "wonderful development for the field," but said there was still a need for a vaccine.
"For HIV vaccine design and development, we've begun to see light at the end of the tunnel after many years of research," Dennis Burton, an immunology professor at Scripps Research, previously told CBS News. "This is a terrible time to cut it off. We're beginning to get close. We're getting good results out of clinical trials."
Burton warned that their HIV vaccine research could not simply be turned back on, even if a future administration decided to change course on HIV funding. He said ongoing experiments would be shuttered, and researchers assembled to study the issue would be forced to refocus their careers on other topics.
"This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research," Burton said.
Teen questioned after family's quadruple murder
Iranians evacuate capital Tehran, some say the regime is frightened
Parents, brother of slain Minnesota lawmaker Melissa Hortman speak about her death
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16 hours ago
- Yahoo
What is a fireball, and how often does rare event occur? See known SC meteorites
The American Meteor Society received over 160 reports in the Southeast − including South Carolina and Georgia − of a fiery object streaking through the skies on June 26. The object, identified later on as a fireball, "exploded 27 miles above West Forest, Georgia, unleashing an energy of about 20 tons of TNT," according to CBS News. Bill Cooke, a lead at NASA's Meteoroid Environment Office, confirmed the fireball, observed before 12:30 p.m., was 3 feet in diameter, weighing more than a ton. No injuries have been reported due to the fireball, although a home in Henry County, Georgia, was struck by debris suspected to be related to the meteor. Here's the difference between a fireball and meteor. Per FossilEra, a meteor is often called a "shooting star" or "falling star" since they appear as a streak of light, produced when a meteoroid enters Earth's atmosphere and vaporizes due to the intense heat caused by friction with air. A meteor is a visible atmospheric phenomenon that results from the meteor's swift entry and disintegration, meaning it is not a physical object. A fireball is a meteor that is significantly brighter than normal meteors, outshining planet Venus. Ground-level rumbles known as sonic booms occur when a fireball explodes, according to EBSCO. Only a small number of meteors that enter the Earth's atmosphere are classified as fireballs. Each day, several thousand meteors of fireball magnitude occur in the Earth's atmosphere, and the majority of them are difficult to observe since they take place over the oceans and uninhabited regions, with many masked by daylight, per the American Meteor Society. Fireballs that occur at night have less of a chance of being seen because there aren't as many people outside to notice them. "Additionally, the brighter the fireball, the more rare is the event. As a general thumb rule, there are only about 1/3 as many fireballs present for each successfully brighter magnitude class, following an exponential decrease." said the American Meteor Society. "Experienced observers can expect to see only about 1 fireball of magnitude -6 or better for every 200 hours of meteor observing, while a fireball magnitude -4 can be expected about once every 20 hours or so." Meteorites are fragments of space rocks like asteroids or comets that survive passing through Earth's atmosphere, landing on the surface. Before entering the atmosphere, they are called meteoroids, and can vary in size from tiny dust grains to large asteroids. The South Carolina Department of Natural Resources listed the following records regarding meteorite occurrence within the state on their website: 1843: Achondrite, Bishopville 1844: Octahedrite, Ruff's Mountain, Newberry County 1849: Ataxite, Chesterville 1857: Octahedrite, Laurens County 1880: Octahedrite, Lexington County 1933: Chondrite, Cherokee Springs The Greenville News reached out to NASA for a comment for this story, but did not receive a response. Nina Tran covers trending topics for The Greenville News. Reach her via email at ntran@ This article originally appeared on Greenville News: Fireball and meteor: The difference, how to tell them apart